T cell gene therapy - Cell Genesys

Drug Profile

T cell gene therapy - Cell Genesys

Alternative Names: Anti-HIV T cell gene therapy

Latest Information Update: 12 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Genesys
  • Class Antivirals; Gene therapies
  • Mechanism of Action CD4 agonists; CD8 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; HIV-1 infections

Most Recent Events

  • 14 Aug 2001 Discontinued-II for HIV-1 infections in USA (IV-infusion)
  • 29 May 2001 Cell Genesys is seeking a collaborator for T cell gene therapy for HIV infection
  • 27 Sep 1999 Results of a clinical study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top